OPTR announced today that data being presented at the American Society of Health-System Pharmacists 46th Midyear Clinical Meeting demonstrate that the economic value of DIFICID® (fidaxomicin) tablets to the U.S. health system meets or exceeds the price per day to treat Clostridium difficile-associated diarrhea (CDAD) compared to vancomycin. Results showed that when data accounting for the cost and frequency of disease recurrence are factored into an economic equation weighing the value of DIFICID against three common regimens of vancomycin, the overall value provided by DIFICID, which ranged from 95% to 141% of the drug's wholesale acquisition cost (WAC), indicates it is cost saving in many treatment scenarios.
"Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients in North America and Europe, and the incidence and severity of the disease have increased significantly over the past decade," said Dr. David A. Sclar, Boeing Distinguished Professor of Health Policy and Administration, Washington State University. "Fidaxomicin represents an advance in the treatment of CDAD. Our results indicate that from the perspective of the U.S. health system, use of fidaxomicin is financially prudent."